Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China
Kai Ding ,* Hong Yu ,* Yuan-Yuan Shao, Li-Yan Li, Chao-Meng Wang, Jia Song, Li-Juan Li, Rong Fu Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of China*These authors contributed equally to this workCorrespondence: Rong Fu Tel +86-18...
Main Authors: | Ding K, Yu H, Shao YY, Li LY, Wang CM, Song J, Li LJ, Fu R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/real-world-data-on-the-efficacy-and-safety-of-ixazomib-based-therapy-i-peer-reviewed-article-CMAR |
Similar Items
-
Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01) -
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
by: Jian Hou, et al.
Published: (2017-07-01) -
Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01) -
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
by: Richardson PG, et al.
Published: (2017-08-01) -
A phase 1/2 study of ixazomib as a replacement for bortezomib or carfilzomib for multiple myeloma patients recently relapsed or refractory to their last combination regimen containing either bortezomib or carfilzomib
by: Forouzan, Eli
Published: (2020)